Prediction of absorbed dose by tumors and critical organs after Lu-177-DOTATATE therapy using pretherapeutic Ga-68-DOTATOC PET/CT

Article Figures & Data

Absorbed dose after Lu-177-DOTATATE therapy and correlation analysis with Ga-68-DOTATOC PET/CT

Lesion	Number	Estimated absorbed dose of Lu-177-DOTATATE therapy	SUVmean of Ga-68-DOTATOC PET/CT	Spearmanâ€™s correlation coefficient	P-value
Tumor (total)	95	19.2 ± 16.1 Gy	19.9 ± 11.4	0.77	< 0.001*
Hepatic metastasis	60	24.3 ± 15.8 Gy	23.0 ± 11.7	0.63	< 0.001*
Other tumor	35	10.3 ± 12.4 Gy	14.0 ± 8.0	0.87	< 0.001*
Critical organ (total)	51	2.7 ± 2.5 Gy	4.3 ± 3.1	0.62	< 0.001*
Kidney	25	4.7 ± 1.7 Gy	5.6 ± 2.7	0.46	0.022*
Liver	13	1.2 ± 1.2 Gy	5.6 ± 1.8	0.49	0.090
Bone marrow	13	0.2 ± 0.2 Gy	0.4 ± 0.2	0.08	0.788